CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
High ImpactOriginal article

Bristol gains accelerated approval of iberdomide for multiple myeloma

RegulatoryapprovediberdomidePositive
AI Analysis

Summary

Bristol Myers Squibb received accelerated FDA approval for iberdomide for the treatment of multiple myeloma, a significant regulatory milestone for the company's oncology portfolio.

Outcome Details

accelerated approval

Importance:8/10
Sentiment:
0.85
FDA approvalaccelerated approvalmultiple myelomaoncology
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on August 13, 2026 9:29 PM

Read Original